COMMUNIQUÉS West-GlobeNewswire
-
Inovalon and the University of Maryland Center for Health Information & Decision Systems Collaborate on Machine Learning and Neural Network Applications
20/11/2017 - 13:55 -
Optinose to Report Third Quarter 2017 Financial Results and Operational Highlights on November 27, 2017
20/11/2017 - 13:30 -
Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
20/11/2017 - 13:30 -
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
20/11/2017 - 13:30 -
Beleave Announces $5 Million Non-Brokered Private Placement of Units
20/11/2017 - 13:25 -
THC Therapeutics in Partnership With ADVFN Announces Formation of New Company - MJAC Investorshub International Conferences Ltd
20/11/2017 - 13:20 -
Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial
20/11/2017 - 13:01 -
Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
20/11/2017 - 13:00 -
Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial
20/11/2017 - 13:00 -
Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference
20/11/2017 - 13:00 -
Recro Pharma Secures $100 Million Credit Facility
20/11/2017 - 13:00 -
ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting
20/11/2017 - 13:00 -
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
20/11/2017 - 13:00 -
ProQR Announces Results for the Third Quarter of 2017
20/11/2017 - 13:00 -
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
20/11/2017 - 13:00 -
Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
20/11/2017 - 13:00 -
Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia
20/11/2017 - 13:00 -
Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
20/11/2017 - 12:00 -
Orphazyme A/S: Completion of the Offering and registration of share capital increase
20/11/2017 - 11:46
Pages